Clinical Trial Detail

NCT ID NCT01572038
Title A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

breast adenocarcinoma

Therapies

Pertuzumab + Trastuzumab

nab-paclitaxel

Docetaxel

Paclitaxel

Age Groups: adult

Additional content available in CKB BOOST